First exploration of the on-treatment changes in tumor and organ uptake of a radiolabeled anti PD-L1 antibody during chemoradiotherapy in patients with non-small cell lung cancer using whole body PET

First exploration of the on-treatment changes in tumor and organ uptake of a radiolabeled anti PD-L1 antibody during chemoradiotherapy in patients with non-small cell lung cancer using whole body PET

Background In patients with locally advanced unresectable non-small cell lung cancer (NSCLC), durvalumab, an anti-programmed cell death ligand-1 (PD-L1) antibody, has shown improved overall survival when used as consolidation therapy following concurrent chemoradiotherapy (CRT). However, it is uncle...

Full description

Bibliographic Details
Main Authors: Tanja D de Gruijl, Teodora Radonic, Marc C Huisman, Idris Bahce, Johanna E E Pouw, Sayed M S Hashemi, Jessica E Wijngaarden, Maarten Slebe, Daniela E Oprea-Lager, Gerben J C Zwezerijnen, Danielle Vugts, Ezgi B Ulas, Suresh Senan, C Willemien Menke-van der Houven van Oordt
Format: Article
Language:English
Published: BMJ Publishing Group 2024-02-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/2/e007659.full

Internet

https://jitc.bmj.com/content/12/2/e007659.full

Similar Items